<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567550</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-314-2202</org_study_id>
    <nct_id>NCT04567550</nct_id>
  </id_info>
  <brief_title>RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)</brief_title>
  <acronym>ALTITUDE</acronym>
  <official_title>A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via a Single Suprachoroidal Space (SCS) Injections in Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)(ALTITUDE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RGX-314 is being developed as a novel one-time gene therapy treatment for the treatment of&#xD;
      diabetic retinopathy, a chronic and progressive complication of diabetes mellitus. Diabetic&#xD;
      retinopathy is a sight-threatening disease characterized in the early stages by neuronal and&#xD;
      vascular dysfunction in the retina, and later by neovascularization that leads to further&#xD;
      deterioration of functional vision. Despite the availability of current treatments, diabetic&#xD;
      retinopathy remains the leading cause of vision loss in working-age adults, those between the&#xD;
      ages of 20 and 74. Existing treatment with anti-VEGF agents, although shown to be effective,&#xD;
      are limited by short therapeutic half-lives, which then require frequent intravitreal&#xD;
      injections over the patient's lifetime, resulting in increased risk of associated adverse&#xD;
      events and significant treatment burden. Due to the burden of treatment, patients often do&#xD;
      not closely adhere to treatment regimens and experience sub-optimal outcomes and a decline in&#xD;
      vision. RGX-314 is being developed as a potential one time treatment for diabetic&#xD;
      retinopathy, which may deliver advantages over conventional treatments, such as potentially&#xD;
      providing a longer duration of therapeutic effect and intervening at an earlier stage of the&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety&#xD;
      and tolerability of RGX-314 gene therapy in subjects with DR without CI-DME. Approximately 60&#xD;
      participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3&#xD;
      cohorts. Participants will be randomized in Cohorts 1 and 2 to receive RGX-314 or to be&#xD;
      observed, and participants enrolled in Cohorts 3 will receive RGX-314. Cohort 1 will evaluate&#xD;
      RGX-314 Dose 1, and Cohorts 2 and 3 will evaluate RGX-314 Dose 2. Participants who are&#xD;
      randomized to be observed in Cohorts 1 and 2 will be offered RGX-314 after completing the&#xD;
      study. Efficacy will be the primary focus of the study. Participants will be evaluated for&#xD;
      safety and tolerability of RGX-314 throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of RGX-314 on DR by the Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of participants achieving a 2-step or greater improvement in DR by Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at Week 48 scored from Levels 10-85 with higher levels indicating greater DR severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of RGX-314 on DR (ETDRS-DRSS) over time</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of participants achieving improvement or worsening in DR per ETDRS-DRSS grading through week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of RGX-314</measure>
    <time_frame>48 weeks</time_frame>
    <description>Assess the incidence of overall and ocular Adverse Events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the need for additional Standard of Care (SOC) intervention due to ocular diabetic complications</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of participants with sight-threatening ocular diabetic complications requiring additional SOC intervention (anti-VEGF, Pan-Retinal Photocoagulation (PRP), laser, steroids, or surgical intervention)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Retinopathy (DR)</condition>
  <arm_group>
    <arm_group_label>Observation Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Treatment Arm (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Treatment Arm (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RGX-314 Dose 1</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)</description>
    <arm_group_label>RGX-314 Treatment Arm (Dose 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RGX-314 Dose 2</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)</description>
    <arm_group_label>RGX-314 Treatment Arm (Dose 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 25-89 years of age with a diabetic retinopathy diagnosis of nonproliferative&#xD;
             diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) secondary to&#xD;
             diabetes mellitus Type 1 or 2 for which PRP or anti-VEGF injections can be safely&#xD;
             deferred for at least 6 months&#xD;
&#xD;
          -  Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)&#xD;
             letter score in the study eye of â‰¥69 letters (approximate Snellen equivalent of 20/40&#xD;
             or better)&#xD;
&#xD;
          -  Prior history of CI-DME in the study eye is acceptable.&#xD;
&#xD;
          -  Must be willing and able to provide written, signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neovascularization in the study eye from a cause other than DR.&#xD;
&#xD;
          -  Presence of any active CI-DME.&#xD;
&#xD;
          -  Active or history of retinal detachment in the study eye.&#xD;
&#xD;
          -  Any evidence or documented history of PRP or retinal laser in the study eye.&#xD;
&#xD;
          -  Patients who had a prior vitrectomy surgery.&#xD;
&#xD;
          -  Women of childbearing potential.&#xD;
&#xD;
        Note: Other inclusions/exclusions criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-860-0117</phone>
    <email>patientadvocacy@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Location</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Phoenix Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bakersfield Location</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bakersfield Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Location</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beverly Hills Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campbell Location</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Campbell Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain View Location</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mountain View Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasadena Location</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pasadena Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poway Location</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Poway Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Location</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Santa Barbara Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta Location</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Augusta Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oak Forest Location</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Oak Forest Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baltimore Location</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Baltimore Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hagerstown Location</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hagerstown Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Location</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Boston Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reno Location</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reno Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teaneck Location</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teaneck Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Location</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Albuquerque Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Durham Location</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Durham Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Philadelphia Location</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philadelphia Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Germantown Location</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Germantown Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Location</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Austin Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodlands Location</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Woodlands Site PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Choroidal Effusions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

